ENANTIOSELECTIVE DETERMINATION OF MIANSERIN AND ITS DESMETHYL METABOLITE IN PLASMA DURING TREATMENT OF DEPRESSED JAPANESE PATIENTS

被引:14
作者
TYBRING, G
OTANI, K
KANEKO, S
MIHARA, K
FUKUSHIMA, Y
BERTILSSON, L
机构
[1] KAROLINSKA INST,HUDDINGE HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,HUDDINGE,SWEDEN
[2] HIROSAKI UNIV HOSP,DEPT NEUROPSYCHIAT,HIROSAKI,AOMORI 036,JAPAN
关键词
MIANSERIN; DESMETHYLMIANSERIN; ENANTIOMERS; CHIRAL SEPARATION;
D O I
10.1097/00007691-199510000-00013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A method for the analysis of the enantiomers of mianserin and its main metabolite desmethylmianserin in plasma using a chiral AGP high performance liquid chromatography column is described. In the majority of 66 depressed Japanese patients, the concentration of the more active S(+)mianserin was higher than that of the R(-)-enantiomer. The mean SIR ratio was 1.9 +/- 0.9 (SD) (range 0.5-4.8). The concentration of S(+)- varied between 19 and 223 nM, while that of the R(-)-mianserin varied between 14 and 72 nM. Among 42 of the 66 plasma samples in which the enantiomers of desmethylmianserin could be measured, the R-form predominated in all but one. S-Desmethylmianserin was in most of the samples present in concentrations of <10 nM (limit of detection). Analysis of the enantiomers of mianserin and desmethylmianserin might allow the establishment of a closer relationship between plasma levels and clinical effects.
引用
收藏
页码:516 / 521
页数:6
相关论文
共 11 条
[1]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[2]   STEREOSELECTIVE DISPOSITION OF MIANSERIN IS RELATED TO DEBRISOQUIN HYDROXYLATION POLYMORPHISM [J].
DAHL, ML ;
TYBRING, G ;
ELWIN, CE ;
ALM, C ;
ANDREASSON, K ;
GYLLENPALM, M ;
BERTILSSON, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :176-183
[3]   STEREOSELECTIVE DISPOSITION OF RACEMIC E-10-HYDROXYNORTRIPTYLINE IN HUMAN-BEINGS [J].
DAHLPUUSTINEN, ML ;
PERRY, TL ;
DUMONT, E ;
VONBAHR, C ;
NORDIN, C ;
BERTILSSON, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (06) :650-656
[4]  
DEJONGH GD, 1981, DRUG METAB DISPOS, V9, P48
[5]   BIOTRANSFORMATION OF MIANSERIN IN LABORATORY-ANIMALS AND MAN [J].
DELBRESSINE, LPC ;
MOONEN, MEG ;
KASPERSEN, FM ;
JACOBS, PL ;
WAGENAARS, GL .
XENOBIOTICA, 1992, 22 (02) :227-236
[6]  
KALOW W, 1994, ADV DRUG RES, V25, P1
[7]  
NAWISHY S, 1981, LANCET, V2, P871
[8]   STEADY-STATE PLASMA-CONCENTRATIONS OF MIANSERIN AND ITS MAJOR ACTIVE METABOLITE, DESMETHYLMIANSERIN [J].
OTANI, K ;
SASA, H ;
KANEKO, S ;
KONDO, T ;
FUKUSHIMA, Y .
THERAPEUTIC DRUG MONITORING, 1993, 15 (02) :113-117
[9]  
OTANI K, 1991, HUMAN PSYCHOPHARMACO, V5, P243
[10]   THE POTENTIAL THERAPEUTIC ROLE OF THE ENANTIOMERS AND METABOLITES OF MIANSERIN [J].
PINDER, RM ;
VANDELFT, AML .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 :S269-S276